On September 26th, Anzhen Hospital witnessed an important milestone in the medical technology field - the launch meeting of the Class III HA medical device clinical trial. This meeting marks the official partnership between Xienfei (Beijing) Trading Co., Ltd., Beijing Huanmu Medical Technology Co., Ltd., and Beijing Anzhen Hospital Affiliated to Capital Medical University, entering a new chapter of deep cooperation.

The Department of Plastic Surgery, Aesthetics and Laser Medicine at Beijing Anzhen Hospital Affiliated to Capital Medical University was established in 1983 and has a thirty-year history. Initially established as a laser department, it was one of the earliest professional departments in China to apply advanced laser technology in clinical surgical treatment. The department has not only steadily developed in the domestic market but also actively engages in international medical beauty exchanges and cooperation, continuously improving its professional level and international influence. This clinical trial launch meeting brings together industry elites and cutting-edge technology, with nearly 200 subjects expected to participate. This is not only a comprehensive test of product performance but also a strong endorsement of the scientific nature and safety of Xienfei's upcoming new products.

REJUVIEL, originating from Korea's PharmaResearch company, is a series of injectable cross-linked sodium hyaluronate products, including three series. Among them, the C series products are expected to launch in 2025, bringing a new wave of beauty revolution to the market.

Currently, Xienfei (Beijing) Trading Co., Ltd. is actively engaged in the clinical trial of this project, with the product expected to launch in 2026, named as the V series. The launch of the V series not only marks another major breakthrough in Xienfei's product layout in the injectable cross-linked sodium hyaluronate field but also represents a comprehensive upgrade in the depth and breadth of its product line. As various series of REJUVIEL products successively debut, consumers will have more choices and experience more personalized, efficient, and safe beauty solutions. The launch of this clinical trial demonstrates Xienfei's firm belief in continuous exploration and innovation in the medical beauty and medical device field, indicating that its new products will lead industry trends and open a new chapter in healthy beauty with safer and more efficient solutions.